ESTRO meets Asia 2024 - Abstract Book

S164

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

(Figure 2.)

Conclusion:

Over 80% of NPC patients survive without disease progression 24 months after diagnosis and are followed with a favorable sOS. Except for stage IVA, most patients achieving PFS24 share indistinguishable survival with the background population. Nonetheless, individuals with early recurrence experience markedly reduced survival. These notable outcome disparities underscore the value of PFS24 in NPC risk stratification, patient surveillance, and study design.

Keywords: subsequent survival, loss of lifetime

59

Proffered Paper

Significance of longitudinal EBV-DNA combined with tumor response for nasopharyngeal carcinoma Yang Liu, Junlin Yi

Radiation oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Purpose/Objective: